VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
PLUR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
PLURPluri Inc.
$0.98$9M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
PLUR logo

Pluri Inc.

PLUR
NASDAQ · Cell & Gene Therapy
$0.98
At close - Nov 17, 4:00 PM EST - USD
Market Cap$9M
P/E-0.2x
52W High$4.12
Volume25.6K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Persistent Operational Losses Threaten Pluri Capital Solvency

Pluri Inc. faces a precarious financial outlook characterized by erratic revenue streams and a rapid depletion of its liquidity buffer. The company's pivot toward CDMO services has yet to demonstrate scalability, as evidenced by the persistent inability to achieve positive operating margins.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

PLUR price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

3/12 Beats

EPS beat 3 of last 12 quarters

02

Valuation risk

-101% Peers

P/E is 101% below peer median

03

Market leadership

RS 11 · Lag

Laggard (Underperforming 89% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · May 12

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
PLUR-67.22%
S&P 500 (^GSPC)+7.21%
1-Year Return
PLUR-73.15%
S&P 500 (^GSPC)+10.03%
3-Year Return
PLUR-79.67%
S&P 500 (^GSPC)+61.28%
5-Year Return
PLUR-95.50%
S&P 500 (^GSPC)+53.85%

Growth & profitability

Annual revenue & EPS trend
Revenue FY26
$1M-24.0% YoY
Net income FY26
-$24M-5.5% YoY
Free cash flow FY26
-$20M-2.0% YoY
Operating margin FY26
-2454.5%-794.6 pts YoY
ROIC (FY26)-90.7%
Avg ROIC 5Y-61.1%
ROE (FY26)-
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate3/12 (38%)
Revenue Beat Rate1/12 (14%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q1 2026Latest
Feb 12, 2026
-$0.71-9.2%
vs -$0.65
$198,000-69.0%
vs $638,000
Q4 2025
Nov 12, 2025
-$0.65+12.2%
vs -$0.74
$316,000-50.5%
vs $638,000
Q4 2025
Sep 17, 2025
-$2.62-303.1%
vs -$0.65
$398,000-37.6%
vs $638,000
Q2 2025
May 13, 2025
-$0.94-28.8%
vs -$0.73
$427,000+6.8%
vs $400,000
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·Oct 30, 2026
Pluri Inc. (PLUR) Discusses Commercialization Strategy, ZEO ScientifiX Transaction and Financial Flexibility Transcript

Pluri Inc. (PLUR) Discusses Commercialization Strategy, ZEO ScientifiX Transaction and Financial Flexibility Transcript

GlobeNewsWire·Oct 26, 2026
Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine

Established U.S. commercial platform: ZEO contributes biologics manufacturing, scientific expertise, an existing product portfolio, physician relationships, and dedicated sales, marketing, and educational resources. Complementary technology and development capabilities: Pluri brings extensive experience in cell-based product development, clinical experience extending through Phase III trials and scalable manufacturing methods and expertise developed through its proprietary 3D cell-expansion platform.

GlobeNewsWire·Oct 13, 2026
Ever After Foods and Roslin Technologies Achieve Major Leap in Cultivated Meat Productivity

HAIFA, Israel and EDINBURGH, Scotland, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Ever After Foods (EAF) and Roslin Technologies today announced results from their joint cultivated meat production program. Combining Roslin Technologies' advanced cell platform with Ever After Foods' proprietary Edible Packed Bed (EPB™) technology, the companies demonstrated substantial gains in protein and biomass productivity while producing structured tissue directly within a scalable and food-grade process.

Defense World·Sep 16, 2026
Pluri (PLUR) to Post Earnings on Wednesday

Pluri (NASDAQ: PLUR - Get Free Report) is expected to post its results after the market closes on Wednesday, September 23rd. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $0.6550 million for the quarter. Pluri (NASDAQ: PLUR - Get Free Report) last released its earnings results on Thursday, September 10th. The

Filtered for Pluri Inc.More Headlines
04

Compare before deciding

Benchmark PLUR against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Pluri Inc. (PLUR)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
PLUR logoPLURPluri Inc.Current
$0.98$8.81M-0.25-23.95%-2265.14%——
FATE logoFATEFate Therapeutics, Inc.
$1.02$118.89M-1.01-51.24%-2619.64%-73.92%—
NTLA logoNTLAIntellia Therapeutics, Inc.
$9.78$1.1B-3.2216.92%-805.75%-64.73%—
BEAM logoBEAMBeam Therapeutics Inc.
$20.65$2.12B-20.19120.01%-73.04%-9.69%—
EDIT logoEDITEditas Medicine, Inc.
$1.83$280.84M-3.8925.39%-144.95%-130.43%—
CRSP logoCRSPCRISPR Therapeutics AG
$40.15$3.87B-8.52-89.97%-1812.07%-25.59%—

Compare PLUR vs Peers

Pluri Inc. (PLUR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs FATE

Most directly comparable listed peer for PLUR.

Scale Benchmark

vs TMO

Larger-name benchmark to compare PLUR against a more recognizable public peer.

Peer Set

Compare Top 5

vs FATE, NTLA, BEAM, EDIT

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

PLUR SEC Filings & Documents

Pluri Inc. (PLUR) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 28, 2026·SEC

Material company update

Aug 17, 2026·SEC

Material company update

Mar 27, 2026·SEC

10-K Annual Reports

4
FY 2026

Sep 10, 2026·SEC

FY 2025

Sep 17, 2025·SEC

FY 2024

Sep 18, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 14, 2026·SEC

FY 2026

Feb 12, 2026·SEC

FY 2025

Nov 12, 2025·SEC

Get notified when PLUR posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

PLUR Frequently Asked Questions

Pluri Inc. (PLUR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Pluri Inc.'s revenue?

Pluri Inc. (PLUR) reported $2.1M in revenue over the trailing twelve months. Revenue was $1.0M in fiscal year 2026.

How fast is Pluri Inc. growing?

Pluri Inc. (PLUR) grew revenue by 61.4% over the trailing twelve months, compared with the twelve months before.

Is PLUR profitable?

No. Pluri Inc. (PLUR) reported a net loss of $48.5M over the trailing twelve months.

Dividend & Returns
What is Pluri Inc.'s free cash flow?

Pluri Inc. (PLUR) had negative free cash flow of $19.2M over the trailing twelve months.

What if you invested $1,000 in PLUR back in 2002?

Total return calculator · dividends reinvested · 24+ years of data

See returns →